PCSK9 and leptin plasma levels in anorexia nervosa.
Anorexia nervosa
Leptin
Lipids
PCSK9
Journal
Hormones (Athens, Greece)
ISSN: 2520-8721
Titre abrégé: Hormones (Athens)
Pays: Switzerland
ID NLM: 101142469
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
received:
12
04
2023
accepted:
02
11
2023
medline:
8
2
2024
pubmed:
24
11
2023
entrez:
24
11
2023
Statut:
ppublish
Résumé
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a regulator of low-density-lipoprotein cholesterol (LDL-C), a major risk factor for cardiovascular (CV) disease. Since the hormone leptin has been suggested as having a role in CV risk regulation, possibly by modulating LDL receptor expression through the PCSK9 pathway, nutritional status may represent a potential regulator. Thus, evaluation of PCSK9 levels in human eating disorders appears to be of interest. In this report, we evaluate the lipoprotein profile, PCSK9, and leptin levels in subjects affected by anorexia nervosa (AN) to improve our understanding of the metabolic alterations in this disease. We designed a case-control observational study, enrolling 20 anorexic adolescent females and 20 adolescent females without AN as the control group, age- and sex-matched. Subjects affected by AN showed lower BMI, total cholesterol, and LDL-C in comparison to the control group, with lipoprotein levels in the normal range. Furthermore, adolescent girls with AN show significantly higher PCSK9 (+24%, p < 0.005) and lower leptin levels (-43%, p < 0.01), compared to the control group. The findings of increased levels of PCSK9 and reduced leptin levels among AN subjects warrant further research in order to unravel the role of the liver and adipose tissue in the management of PCSK9/LDL metabolism in adolescents affected by AN.
Identifiants
pubmed: 37999906
doi: 10.1007/s42000-023-00504-z
pii: 10.1007/s42000-023-00504-z
doi:
Substances chimiques
PCSK9 protein, human
EC 3.4.21.-
Proprotein Convertase 9
EC 3.4.21.-
Cholesterol, LDL
0
Leptin
0
Proprotein Convertases
EC 3.4.21.-
Serine Endopeptidases
EC 3.4.21.-
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
137-140Informations de copyright
© 2023. The Author(s), under exclusive licence to Hellenic Endocrine Society.
Références
Macchi C, Ferri N, Sirtori CR, Corsini A, Banach M, Ruscica M (2021) Proprotein convertase subtilisin/kexin type 9: a view beyond the canonical cholesterol-lowering impact. Am J Pathol 191:1385–1397
doi: 10.1016/j.ajpath.2021.04.016
pubmed: 34019847
Lakoski S, Lagace T, Cohen J et al (2009) Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 94:2537–2543
doi: 10.1210/jc.2009-0141
pubmed: 19351729
pmcid: 2708952
Roubtsova A, Munkonda M, Awan Z et al (2011) Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol 31:785–791
doi: 10.1161/ATVBAHA.110.220988
pubmed: 21273557
Ruscica M, Ferri N, Macchi C et al (2016) Liver fat accumulation is associated with circulating PCSK9. Ann Med 48:384–391
doi: 10.1080/07853890.2016.1188328
pubmed: 27222915
Krysa J, Ooi T, Proctor S et al (2017) Nutritional and lipid modulation of PCSK9: effects on cardiometabolic risk factors. J Nutr 147:473–481
doi: 10.3945/jn.116.235069
pubmed: 28179493
Sundfor T, Svendsen M, Heggen E et al (2019) BMI modifies the effect of dietary fat on atherogenic lipids: a randomized clinical trial. Am J Clin Nutr 110:832–841
doi: 10.1093/ajcn/nqz113
pubmed: 31216575
Filippatos T, Liberopoulos E, Georgoula M et al (2017) Effects of increased body weight and short-term weight loss on serum PCSK9 levels - a prospective pilot study. Arch Med Sci Atheroscler Dis 2:e46–e51
doi: 10.5114/amsad.2017.70502
pubmed: 29242844
pmcid: 5728080
Saely C, Drexel H (2016) Impact of diet and exercise on proprotein convertase subtilisin/kexin 9: a mini-review. Vasc Pharmacol 87:10–13
doi: 10.1016/j.vph.2016.10.003
Beltowski J (2006) Leptin and atherosclerosis. Atherosclerosis. 189:47–60
doi: 10.1016/j.atherosclerosis.2006.03.003
pubmed: 16580676
Smink FR, van Hoeken D, Hoek HW (2013) Epidemiology, course, and outcome of eating disorders. Curr Opin Psychiatry 26:543–548
doi: 10.1097/YCO.0b013e328365a24f
pubmed: 24060914
Mehler P (2001) Diagnosis and care of patients with anorexia nervosa in primary care settings. Ann Intern Med 134:1048–59
Rigaud D, Tallonneau I, Vergès B (2009) Hypercholesterolaemia in anorexia nervosa: frequency and changes during refeeding. Diabetes Metab 35:57–63
doi: 10.1016/j.diabet.2008.08.004
pubmed: 19101189
Hussain A, Hübel C (2019) Increased lipid and lipoprotein concentrations in anorexia nervosa: a systematic review and meta-analysis. Int J Eat Disord 52:611–629
doi: 10.1002/eat.23051
pubmed: 30920679
pmcid: 6842568
Misra M, Miller KK, Tsai P, Stewart V, End A, Freed N et al (2006) Uncoupling of cardiovascular risk markers in adolescent girls with anorexia nervosa. J Pediatr 149:763–769
doi: 10.1016/j.jpeds.2006.08.043
pubmed: 17137889
Stroe-Kunold E, Buckert M, Friederich HC, Wesche D, Kopf S, Herzog W, Wild B (2016) Time course of leptin in patients with anorexia nervosa during inpatient treatment: longitudinal relationships to BMI and psychological factors. PLoS One 11:e0166843
doi: 10.1371/journal.pone.0166843
pubmed: 28030575
pmcid: 5193359
Weinbrenner T, Züger M, Jacoby GE, Herpertz S, Liedtke R, Sudhop T, Gouni-Berthold I, Axelson M, Berthold HK (2004) Lipoprotein metabolism in patients with anorexia nervosa: a case-control study investigating the mechanisms leading to hypercholesterolaemia. Br J Nutr 91:959–69
Purnell JQ, Kahn SE, Albers JJ, Nevin DN, Brunzell JD, Schwartz RS (2000) Effect of weight losswith reduction of intra-abdominal fat on lipid metabolism in older men. J Clin Endocrinol Metab 85(3):977–982
Miyai K, Yamamoto T, Azukizawa M, Ishibashi K, Kumahara Y (1975) Serum thyroid hormones and thyrotropin in anorexia nervosa. J Clin Endocrinol Metab 40:334–338
doi: 10.1210/jcem-40-2-334
pubmed: 804141
Funcke J, Scherer P (2019) Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication. J Lipid Res 60(10):1648–1684
doi: 10.1194/jlr.R094060
pubmed: 31209153
pmcid: 6795086
Jeong H, Lee H, Kim K, Kim Y, Yoon D et al (2008) Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res 49:399–409
doi: 10.1194/jlr.M700443-JLR200
pubmed: 17921436